Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Grosso

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
ESMO Open|April 15, 2022
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 studyM Mark, S Rusakiewicz, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Y Metaxas, M Früh, E I Eboulet, et al.
ESMO Open|December 4, 2022
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesotheliomaS Canova, G L Ceresoli, F Grosso, et al.
International Journal of Radiation Oncology, Biology, Physics|September 26, 2013
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer modelSatoshi Wada, Timothy J Harris, Erik Tryggestad, et al.
Blood|March 30, 2007
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsMonica V Goldberg, Charles H Maris, Edward L Hipkiss, et al.
Oncogene|November 12, 2013
Mode of action of trabectedin in myxoid liposarcomasS Di Giandomenico, R Frapolli, E Bello, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 18, 2009
Tc17 CD8 T cells: functional plasticity and subset diversityHung-Rong Yen, Timothy J Harris, Satoshi Wada, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Science Advances|February 2, 2022
Liberating a hidden antiferroelectric phase with interfacial electrostatic engineeringJulia A Mundy, Bastien F Grosso, Colin A Heikes, et al.
International Journal of Cancer|August 2, 2011
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agentsS Uboldi, S Bernasconi, M Romano, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
ESMO Open|April 15, 2022
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 studyM Mark, S Rusakiewicz, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 23, 2020
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Y Metaxas, M Früh, E I Eboulet, et al.
ESMO Open|December 4, 2022
Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesotheliomaS Canova, G L Ceresoli, F Grosso, et al.
International Journal of Radiation Oncology, Biology, Physics|September 26, 2013
Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer modelSatoshi Wada, Timothy J Harris, Erik Tryggestad, et al.
Blood|March 30, 2007
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsMonica V Goldberg, Charles H Maris, Edward L Hipkiss, et al.
Oncogene|November 12, 2013
Mode of action of trabectedin in myxoid liposarcomasS Di Giandomenico, R Frapolli, E Bello, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 18, 2009
Tc17 CD8 T cells: functional plasticity and subset diversityHung-Rong Yen, Timothy J Harris, Satoshi Wada, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Science Advances|February 2, 2022
Liberating a hidden antiferroelectric phase with interfacial electrostatic engineeringJulia A Mundy, Bastien F Grosso, Colin A Heikes, et al.
International Journal of Cancer|August 2, 2011
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agentsS Uboldi, S Bernasconi, M Romano, et al.
Pageof 10